Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Erlotinib
United Therapeutics Europe Ltd
Non-Small Cell Lung Cancer
1 trial -
Erlotinib
Hoffmann-La Roche
Non-Small Cell Lung Cancer
1 trial -
Famitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Fianlimab
Regeneron UK Limited
Resectable Non-small Cell Lung Cancer
1 trial -
Furmonertinib
The First People's Hospital of Lianyungang
Non-Small Cell Lung Cancer
1 trial -
Gilteritinib
Astellas Pharma Inc
Non-Small-Cell Lung Cancer
1 trial -
Gimistotug
BEONE MEDICINES AUS PTY LTD
Non-Small Cell Lung Cancer
1 trial -
Hypofractionated radiation/chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
IBI363
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non Small Cell Lung Cancer
1 trial -
INC280
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
1 trial -
ISIS EIF4E Rx
IONIS PHARMACEUTICALS INC
Non-small Cell Lung Cancer
1 trial -
Icotinib
The First People's Hospital of Lianyungang
Non-Small Cell Lung Cancer
1 trial -
Ivonescimab
Summit Therapeutics
Non-Small Cell Lung Cancer
3 trials -
JIN-A02
INTENSITY THERAPEUTICS, INC.
EGFR Mutant Advanced Non-small Cell Lung Cancer
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Non Small Cell Lung Cancer
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Metastatic Non Small Cell Lung Cancer
1 trial -
MaaT033 capsule
Regeneron UK Limited
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Mifepristone
CORCEPT THERAPEUTICS INC
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
NAP (Naptumomab estafenatox)
BRIGHT MINDS BIOSCIENCES INC.
Non-small Cell Lung Cancer
1 trial -
NEO-201 in combination with pembrolizumab
Chongqing Precision Biotech Co., Ltd
Non Small Cell Lung Cancer
1 trial -
NK cell and PD-1 antibody
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
NKTR-214
Nektar Therapeutics UK Limited
Non-Small Cell Lung Cancer
1 trial -
Osimertinib + Savolitinib
AstraZeneca
Non-Small Cell Lung Cancer
1 trial -
PD-1 inhbitor+SHR0302
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.